NCT02492568View on ClinicalTrials.gov

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

pembrolizumab

RADIATION

Stereotactic Body Radiation Therapy

Trial Locations (1)

1066 CX

Antoni van Leeuwenhoek (NKI-AVL), Amsterdam

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT02492568 - Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC | Biotech Hunter | Biotech Hunter